From obesity to substance abuse: Therapeutic opportunities for 5-HT 2C receptor agonists

Trends in Pharmacological Sciences

Volumn 34, Issue 10, 2013, Pages 560-570

  Higgins, Guy A ^a,b   Sellers, Edward M ^c   Fletcher, Paul J ^b,d  

^a InterVivo Solutions Inc   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c DecisionLine   (Canada)

^d CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

addiction; lorcaserin; obesity; serotonin

Indexed keywords

2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; 8,9 DICHLORO 2,3,4,4A TETRAHYDRO 1H PYRAZINO[1,2 A]QUINOXALIN 5(6H) ONE; AMFEBUTAMONE; CHOLESTEROL; COCAINE; CP 80910; DEXFENFLURAMINE; FENFLURAMINE; KETAMINE; LORCASERIN; LOW DENSITY LIPOPROTEIN; MECAMYLAMINE; NICOTINE; OLANZAPINE; PLACEBO; PROOPIOMELANOCORTIN; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN AGONIST; SIBUTRAMINE; UNCLASSIFIED DRUG; VABICASERIN; VARENICLINE; VOLINANSERIN; YOHIMBINE; ZOLPIDEM;

COCAINE DEPENDENCE; DIZZINESS; DOPAMINE RELEASE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG SEEKING BEHAVIOR; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROPHYSIOLOGY; ENERGY BALANCE; FOOD INTAKE; HEADACHE; HUMAN; HYPOTHALAMUS; IMPULSE CONTROL DISORDER; NAUSEA; NEUROCHEMISTRY; NONHUMAN; OBESITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREFRONTAL CORTEX; PRIORITY JOURNAL; REVIEW; TASK PERFORMANCE; TOBACCO DEPENDENCE; VENTRAL TEGMENTUM;

EID: 84885181698     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2013.08.001     Document Type: Review

References (117)

1. B.J. Jones, and T.P. Blackburn The medical benefit of 5-HT research Pharmacol. Biochem. Behav. 71 2002 555 568
2. 2C receptor modulators: a patent survey Expert Opin. Ther. Pat. 20 2010 1429 1455
3. 2C ligands: recent progress Prog. Med. Chem. 46 2008 281 390
4. P.J. Kenny Common cellular and molecular mechanisms in obesity and drug addiction Nat. Rev. Neurosci. 12 2011 638 651
5. N.D. Volkow, and R.A. Wise How can drug addiction help us understand obesity? Nat. Neurosci. 8 2005 555 560
6. N.D. Volkow, and C.P. O'Brien Issues for DSM-V: should obesity be included as a brain disorder? Am. J. Psychiatry 164 2007 708 710
7. J.E. Henningfield Tobacco dependence and withdrawal: science base, challenges and opportunities for pharmacotherapy Pharmacol. Ther. 123 2009 1 16
8. B.A. Syed, and K. Chaudhari Smoking cessation drugs market Nat. Rev. Drug Discov. 12 2013 97 98
9. A.S. Garfield, and L.K. Heisler Pharmacological targeting of the serotonergic system for the treatment of obesity J. Physiol. 587 2009 49 60
10. R.B. Rothman Dopamine/serotonin releasers as medications for stimulant addictions Prog. Brain Res. 172 2008 385 406
11. C.P. Muller The role of serotonin in drug addiction C.P. Muller, B.L. Jacobs, Handbook of Behavioural Neurobiology of Serotonin 2010 Academic Press 507 545
12. D.J. Heal Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine Int. J. Obes. Relat. Metab. Disord. 22 Suppl. 1 1998 S18 S28
13. D.J. Heal Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders Br. J. Clin. Pharmacol. 68 2009 861 874
14. G.A. Kennett, and P.G. Clifton New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier? Pharmacol. Biochem. Behav. 97 2010 63 83
15. J.R. Hughes Antidepressants for smoking cessation Cochrane Database Syst. Rev. 1 2007 CD000031
16. K.A. VanBuskirk, and M.N. Potenza The treatment of obesity and its co-occurrence with substance use disorders J. Addict. Med. 4 2010 1 10
17. R. Tao Effects on serotonin in rat hypothalamus of D-fenfluramine, aminorex, phentermine and fluoxetine Eur. J. Pharmacol. 445 2002 69 81
18. P. Celada Serotonin modulation of cortical neurons and networks Front. Integr. Neurosci. 7 2013 25
19. D. Hoyer International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin) Pharmacol. Rev. 46 1994 157 203
20. D. Hoyer Molecular, pharmacological and functional diversity of 5-HT receptors Pharmacol. Biochem. Behav. 71 2002 533 554
21. C.M. Burns Regulation of serotonin-2C receptor G-protein coupling by RNA editing Nature 387 1997 303 308
22. 2C receptor and its effects on cell signalling, pharmacology and brain function Pharmacol. Ther. 119 2008 7 23
23. 2C receptor agonists: pharmacological characteristics and therapeutic potential J. Pharmacol. Exp. Ther. 286 1998 913 924
24. 2C receptor antagonist J. Med. Chem. 40 1997 3494 3496
25. 2C serotonin receptors Nature 374 1995 542 546
26. 2C receptor antagonist Psychopharmacology (Berl.) 214 2011 941 947
27. 2C receptor mutant mice Psychopharmacology (Berl.) 143 1999 309 314
28. 2C receptors Neuropharmacology 41 2001 200 209
29. R.D. Cone Anatomy and regulation of the central melanocortin system Nat. Neurosci. 8 2005 571 578
30. L.K. Heisler Activation of central melanocortin pathways by fenfluramine Science 297 2002 609 611
31. 2C receptors on cocaine- and food-maintained behavior J. Pharmacol. Exp. Ther. 295 2000 1183 1191
32. 2C receptor agonists on behaviours motivated by food and nicotine and on side effect profiles Psychopharmacology (Berl.) 226 2013 475 490
33. 2C receptor activation inhibits appetitive and consummatory components of feeding and increases brain c-fos immunoreactivity in mice Eur. J. Neurosci. 25 2007 3115 3124
34. S. Fulton Appetite and reward Front. Neuroendocrinol. 31 2010 85 103
35. A.A. Grace Regulation of firing of dopaminergic neurons and control of goal-directed behaviors Trends Neurosci. 30 2007 220 227
36. D.J. Calu The use of the reinstatement model to study relapse to palatable food seeking during dieting Neuropharmacology 2013 10.1016/j.neuropharm.2013.04.030
37. H.R. Berthoud Metabolic and hedonic drives in the neural control of appetite: who is the boss? Curr. Opin. Neurobiol. 21 2011 888 896
38. K.D. Alex, and E.A. Pehek Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission Pharmacol. Ther. 113 2007 296 320
39. 2C receptors Brain Res. 865 2000 85 90
40. 2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat Synapse 36 2000 205 221
41. V. Di Matteo SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system Neuropharmacology 38 1999 1195 1205
42. V. Di Matteo Role of serotonin2C receptors in the control of brain dopaminergic function Pharmacol. Biochem. Behav. 71 2002 727 734
43. 2C receptor agonist Ro60-0175 reduces cocaine self-administration and reinstatement induced by the stressor yohimbine, and contextual cues Neuropsychopharmacology 33 2008 1402 1412
44. 2C receptors influences cocaine-seeking behavior in response to drug-associated stimuli in rats Psychopharmacology (Berl.) 196 2008 15 27
45. 2C receptor activation suppresses the reinforcing efficacy of cocaine and sucrose but differentially affects the incentive-salience value of cocaine- vs sucrose-associated cues Neuropharmacology 61 2011 513 523
46. 2C receptors attenuates cue and cocaine-primed reinstatement of cocaine-seeking behavior in rats Behav. Pharmacol. 18 2007 791 800
47. D.H. Epstein Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure Psychopharmacology (Berl.) 189 2006 1 16
48. Y. Pelloux Reduced forebrain serotonin transmission is causally involved in the development of compulsive cocaine seeking in rats Neuropsychopharmacology 37 2012 2505 2514
49. D.F. Manvich Effects of serotonin 2C receptor agonists on the behavioral and neurochemical effects of cocaine in squirrel monkeys J. Pharmacol. Exp. Ther. 341 2012 424 434
50. 2C receptors reduces the locomotor and rewarding effects of nicotine Psychopharmacology (Berl.) 157 2001 292 298
51. V. Di Matteo Selective stimulation of serotonin2C receptors blocks the enhancement of striatal and accumbal dopamine release induced by nicotine administration J. Neurochem. 89 2004 418 429
52. M. Pierucci Stimulation of serotonin2C receptors blocks the hyperactivation of midbrain dopamine neurons induced by nicotine administration J. Pharmacol. Exp. Ther. 309 2004 109 118
53. D. Quarta The serotonin 2C receptor agonist Ro-60-0175 attenuates effects of nicotine in the five-choice serial reaction time task and in drug discrimination Psychopharmacology (Berl.) 193 2007 391 402
54. 2C receptor ligands on the discriminative stimulus effects of nicotine in rats Eur. J. Pharmacol. 571 2007 156 165
55. 2C receptors suppresses behavioral responses induced by drugs of abuse Nat. Med. 12 2006 324 329
56. 2C receptor compounds on ventral tegmental area self-stimulation thresholds in rats Psychopharmacology (Berl.) 203 2009 579 588
57. 2C receptor activation by WAY 161503 on nicotine-induced place conditioning and locomotor activity in rats Behav. Brain Res. 197 2009 323 330
58. 2A receptor antagonist M100907 on nicotine self-administration and reinstatement Neuropharmacology 62 2012 2288 2298
59. 2C receptor agonists lorcaserin and Ro 60-0175 against nicotine discrimination and dependence in the rat Soc. Neurosci. 2011 Abs. 263.01
60. 2 receptor ligands on depression-like behavior during nicotine withdrawal Neuropharmacology 58 2010 1140 1146
61. 2A receptor blockade Neuropharmacology 61 2011 468 477
62. 2C receptor antagonists in the rat and mouse on premature responding in the five-choice serial reaction time test Psychopharmacology (Berl.) 195 2007 223 234
63. 2C receptor agonist WAY-163909 decreases impulsivity in the 5-choice serial reaction time test Behav. Brain Res. 188 2008 412 415
64. 2C receptor null mutant mice Psychopharmacology (Berl.) 226 2013 561 570
65. N.E. Paterson Impulsive action and impulsive choice are mediated by distinct neuropharmacological substrates in rat Int. J. Neuropsychopharmacol. 15 2012 1473 1487
66. J.C. Talpos A comparison of multiple 5-HT receptors in two tasks measuring impulsivity J. Psychopharmacol. 20 2006 47 58
67. 2A receptor antagonist M100,907 attenuates motor and 'impulsive-type' behaviours produced by NMDA receptor antagonism Psychopharmacology (Berl.) 170 2003 309 319
68. T. Pattij, and L.J. Vanderschuren The neuropharmacology of impulsive behaviour Trends Pharmacol. Sci. 29 2008 192 199
69. 2C receptor antagonist SB242084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding Neuropsychopharmacology 27 2002 576 586
70. L.R. McMahon, and K.A. Cunningham Antagonism of 5-hydroxytryptamine2A receptors attenuates the behavioral effects of cocaine in rats J. Pharmacol. Exp. Ther. 297 2001 357 363
71. K.A. Cunningham Synergism between a serotonin 5-HT2A receptor (5-HT2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction ACS Chem. Neurosci. 4 2013 110 121
72. 2C receptor activation interact to reduce cocaine hyperlocomotion and Fos protein expression in the caudate-putamen Synapse 66 2012 989 1001
73. E.W. Chan Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs Obes. Rev. 14 2013 383 392
74. 2C) receptor agonist, in recreational polydrug users Clin. Pharmacol. Ther. 89 2011 683 692
75. T. Bourcier Lorcaserin: Receptor Pharmacology and Selectivity. Arena Pharmaceuticals NDA 22-529 CR Resubmission 2012 US Food and Drug Administration
76. Drug Enforcement Administration Schedules of Controlled Substances: Placement of lorcaserin into Schedule IV 2013 http://www.federalregister.gov/ articles/2013/05/08/2013-10895
77. N.J. Weissman Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of three phase 3 clinical trials Circ. Cardiovasc. Imaging 6 2013 560 567
78. E. Colman The FDA's assessment of two drugs for chronic weight management N. Engl. J. Med. 367 2012 1577 1579
79. J.H.Q. Shen A 6-week randomized, double-blind, placebo-controlled, comparator referenced, multicenter trial of Vabicaserin in subjects with acute exacerbation of schizophrenia Neuropsychopharmacology 36 2011 S106
80. L. Degenhardt, and W. Hall Extent of illicit drug use and dependence, and their contribution to the global burden of disease Lancet 379 2012 55 70
81. N.D. Volkow, and P. Skolnick New medications for substance use disorders: challenges and opportunities Neuropsychopharmacology 37 2012 290 292
82. 2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control Neuropsychopharmacology 37 2012 1177 1191
83. A.C. Farley Interventions for preventing weight gain after smoking cessation Cochrane Database Syst. Rev. 1 2012 CD006219
84. M. Taylor Cost effectiveness of interventions to reduce relapse to smoking following smoking cessation Addiction 106 2011 1819 1826
85. L.F. Stead, and T. Lancaster Combined pharmacotherapy and behavioural interventions for smoking cessation Cochrane Database Syst. Rev. 10 2012 CD008286
86. K. Cahill Nicotine receptor partial agonists for smoking cessation Cochrane Database Syst. Rev. 4 2012 CD006103
87. E.J. Mills Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis Ann. Med. 44 2012 588 597
88. K.J. Bough Biomarkers for smoking cessation Clin. Pharmacol. Ther. 93 2013 526 538
89. M.V. Morabito Mice with altered serotonin 2C receptor RNA editing display characteristics of Prader-Willi syndrome Neurobiol. Dis. 39 2010 169 180
90. R.T. O'Neil, and R.B. Emeson Quantitative analysis of 5HT(2C) receptor RNA editing patterns in psychiatric disorders Neurobiol. Dis. 45 2012 8 13
91. 2C receptors in CHO-K1 cells Br. J. Pharmacol. 128 1999 13 20
92. W.J. Thomsen Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization J. Pharmacol. Exp. Ther. 325 2008 577 587
93. J. Dunlop Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist J. Pharmacol. Exp. Ther. 337 2011 673 680
94. 2C agonist, shows activity in animal models of antipsychotic activity Neuropharmacology 52 2007 279 290
95. J.C. Jerman Pharmacological characterisation of human 5-HT2 receptor subtypes Eur. J. Pharmacol. 414 2001 23 30
96. J.D. Urban Functional selectivity and classical concepts of quantitative pharmacology J. Pharmacol. Exp. Ther. 320 2007 1 13
97. 2C receptor Mol. Pharmacol. 64 2003 78 84
98. 2C receptor allosteric modulators ACS Chem. Neurosci. 3 2012 538 545
99. P.J. Conn Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders Nat. Rev. Drug Discov. 8 2009 41 54
100. K.A. Berg Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus Mol. Pharmacol. 54 1998 94 104
101. D. Morgan Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: potential utility as antipsychotic medications Neuropharmacology 72 2013 274 281
102. 2C receptor interaction with phosphatase and tensin homolog to allosterically modulate cellular signaling and behavior J. Neurosci. 33 2013 1615 1630
103. 2C receptors in the ventral tegmental area Neuroscience 146 2007 286 297
104. 2C receptor agonist Ro60-0175 into the ventral tegmental area reduces cocaine-induced locomotor activity and cocaine self-administration Neuropsychopharmacology 29 2004 308 318
105. S. Navailles Differential regulation of the mesoaccumbens dopamine circuit by serotonin2C receptors in the ventral tegmental area and the nucleus accumbens: an in vivo microdialysis study with cocaine Neuropsychopharmacology 33 2008 237 246
106. 2C) receptors in the ventrotegmental area inhibits stress-induced but not basal dopamine release in the rat prefrontal cortex J. Neurochem. 82 2002 93 100
107. S. Liu Serotonin2C receptor localization in GABA neurons of the rat medial prefrontal cortex: implications for understanding the neurobiology of addiction Neuroscience 146 2007 1677 1688
108. 2C) receptors attenuates cocaine-seeking behavior Neuropsychopharmacology 35 2010 2037 2048
109. J.W. Dalley Neurobehavioral mechanisms of impulsivity: fronto-striatal systems and functional neurochemistry Pharmacol. Biochem. Behav. 90 2008 250 260
110. 2C receptors inhibit 5-HT neuronal activity via a GABAergic mechanism Br. J. Pharmacol. 149 2006 861 869
111. P.H. Hutson Infusion of the 5-hydroxytryptamine agonists RU24969 and TFMPP into the paraventricular nucleus of the hypothalamus causes hypophagia Psychopharmacology (Berl.) 95 1988 550 552
112. Y. Xu A serotonin and melanocortin circuit mediates D-fenfluramine anorexia J. Neurosci. 30 2010 14630 14634
113. M.G. LeSage Effects of the nicotinic receptor partial agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats Pharmacol. Biochem. Behav. 91 2009 461 467
114. E.C. O'Connor The alpha4beta2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats Psychopharmacology (Berl.) 208 2010 365 376
115. H. Rollema Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid Neuropharmacology 52 2007 985 994
116. M. Zaniewska Effect of varenicline on the acute and repeated locomotor responses to nicotine in rats Synapse 62 2008 935 939
117. L.P. Dwoskin Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent CNS Drug Rev. 12 2006 178 207